Effect of Liraglutide, a Glucagon-Like Peptide-1 Analogue, on Left Ventricular Function in Stable Chronic Heart Failure Patients with and Without Diabetes (LIVE)—a Multicentre, Double-Blind, Randomised, Placebo-Controlled Trial
Anders Jorsal(Steno Diabetes Centers), Lise Tarnow(Steno Diabetes Centers), Jakob Hjort(Aarhus University), Lars Videbæk(Odense University Hospital), Henrik Wiggers(Aarhus University), Morten Schou(British Heart Foundation), Allan Flyvbjerg(Aarhus University Hospital), Pernille Holmager(Copenhagen University Hospital), Caroline Kistorp, Trine Welløv Boesgaard(Steno Diabetes Centers), Roni Nielsen(Aarhus University), Anja Hänselmann(Odense University Hospital), Jacob Eifer Møller(University of Southern Denmark), Jon Rasmussen(University of Copenhagen), Brian Nilsson(Hvidovre Hospital), Rasmus Stilling Tougaard(Aarhus University)
Cited by 561
Related Papers
Targeted Temperature Management at 33°C versus 36°C after Cardiac Arrest
|New England Journal of Medicine|2013|2.8k
Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure
|New England Journal of Medicine|2016|1.7k
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial
|Nature Medicine|2022|889
Type 2 Diabetes Mellitus and Heart Failure: A Position Statement from the Heart Failure Association of the European Society of Cardiology
|European Journal of Heart Failure|2018|716
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
|New England Journal of Medicine|2024|693